Tratamento da esclerose sistêmica com rituximabe: Uma série de 10 casos em centro único

Revista Brasileira de Reumatologia

Volumn 56, Issue 5, 2016, Pages 458-463

  Vilela, Verônica Silva ^a   Maretti, Giselle Baptista ^a   da Silva Gama, Lívia Marques ^a   da Costa, Claudia Henrique ^a   Rufino, Rogério Lopes ^a   Levy, Roger A ^a  

^a UNIVERSIDADE DO ESTADO DO RIO DE JANEIRO   (Brazil)

Author keywords

Modified Rodnan skin score; Pulmonary fibrosis; Rituximab; Systemic sclerosis

Indexed keywords

RITUXIMAB; IMMUNOLOGIC FACTOR;

ARTICLE; CLINICAL ARTICLE; DISEASE COURSE; DISEASE DURATION; HUMAN; LABORATORY TEST; LUNG DISEASE; RETROSPECTIVE STUDY; SCORING SYSTEM; SKIN DISEASE; SYSTEMIC SCLEROSIS; B LYMPHOCYTE; LUNG; TREATMENT OUTCOME;

B-LYMPHOCYTES; HUMANS; IMMUNOLOGIC FACTORS; LUNG; RETROSPECTIVE STUDIES; RITUXIMAB; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME;

EID: 84994318666     PISSN: 04825004     EISSN: 18094570     Source Type: Journal    
DOI: 10.1016/j.rbr.2016.04.001     Document Type: Article

References (21)

1. van den Hogen F, Khanna D, Fransen J, Johnson SR, Baron M,Tyndall A, et al. 2013 Classification Criteria for SystemicSclerosis. Arthritis Rheum. 2013;65(11), 2737047.
2. Gabrielli A, Avvedimento EV, Krieg T. Mechanisms of disease:escleroderma. N Engl J Med. 2009;360(19):1989-2003.
3. Elhai M, Meune C, Avouac J, Kahan A, Allanore Y. Trends inmortality in patients with systemic sclerosis over 40 years: asystematic review and meta-analysis of cohort studies.Rheumatology. 2012;51(6):1017-26.
4. Tashkin D, Elashoff R, Clemments PJ, Goldin J, Roth MD, FurstDE. Cyclophosphamide versus placebo in scleroderma lungdisease. N Engl J Med. 2006;354(25):2655-66.
5. Bérezne D, Valeyre D, Ranque B, Guillevin L, Mouthon L.Interstitial lung disease associated with systemic sclerosis.What is the evidence for efficacy of cyclophosphamide? AnnNY Acad Sci. 2007;1110(27):271-84.
6. Emery P, Fleischmann R, Schechtmann J, Szczepanski L,Racewicz AJ, Van Vollenhoven RF, et al. The efficacy andsafety of rituximab in patients with active rheumatoidarthritis despite metothrexate therapy: results of a phase IIB,randomized, double-blind, placebo-controlled dose rangingstudy. Arhtritis Rheum. 2006;54(5):1390-400.
7. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, HoffmanGS, et al. Rituximab versus cyclophosphamide for ANCAassociated vasculitis. N Engl J Med. 2010;363(3):221-32.
8. Lafyatis R, O'Hara C, Feghali-Bostwick CA, Matteson EB. B cellinfiltration is systemic sclerosis-associated interstitial lungdisease. Arthritis Rheum. 2007;56(9):3167-8.
9. Fleischmajer R, Perlish JS, West WP. Ultrastructure ofcutaneous cellular infiltrates in scleroderma. Arch Dermatol.1977;113(12):1661-6.
10. Lafyatis R, Kissin E, York M, Farina G, Viger K, Fritzler MJ, et al.B cell depletion with rituximab in patients with diffusecutaneous systemic sclerosis. Arthritis Rheum.2009;60(2):578-83.
11. Smith VP, Van Praet JT, Vandooren BR, Vander Cruyssen B,Naeyart JM, Decuman S, et al. Rituximab in diffuse cutaneoussystemic sclerosis: an open-label clinical and histopathologicstudy. Ann Rheum Dis. 2010;69(1):193-7.
12. Smith VP, Piette Y, Van Praet JT, Decuman S, Deschepper E,Elewaut D, et al. Two years results of an open pilot study of a2-treatment course with rituximab in patients with earlysystemic sclerosis with diffuse cutaneous involvement. AnnRheum Dis. 2013;40(1):52-7.
13. Bosello S, De Santis M, Lama G, Spano C, Angelucci C, TolussoB, et al. B cell depletion in diffuse progressive systemicsclerosis: safety, skin socre modification and IL-6 modulationin an up to thirty-six months follow-up open label trial.Arthritis Res Ther. 2010;12(2):1-10. R54.
14. Bosello S, De Luca G, Rucco M, Berardi G, Falcione M, DanzaFM, et al. Long-term efficacy of B cell depletion therapy onlung and skin involvment in diffuse systemic sclerosis. SeminRheum Arhtritis. 2015;44(4):428-36.
15. Giuggioli D, Lummeti F, Colaci M, Fallahi P, Antoneli A, Ferri C,et al. Rituximab in the treatment of patients with systemicsclerosis. Our experience and review of the literature.Autoimmun Rev. 2015;14(11):1072-8.
16. Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C,Kazantzi A, Sirinian C, et al. Experience with rituximab inscleroderma: results from a 1-year, proof-of-principle study.Rheumatology. 2010;49(2):271-80.
17. Jordan S, Distler JHW, Mauer B, Hoscher D, Van Laar JM,Allanore Y, et al. Effects and safety of rituximab in systemicsclerosis: an annals from the European Scleroderma Trial andResearch (EUSTAR) group. Ann Rheum Dis. 2015;74(6):1188-94.
18. Avouac J. Rituximab in systemic sclerosis.www.clinicaltrials.gov Clinical Trials NCT01748084.
19. Clements P, Lachenbruch PA, Seibold JR, White B, Weiner R,Martin R, et al. Inter and intraobserver of total skin score(modified Rodnan TSS) in systemic sclerosis. J Rheum.1995;22(7):1281-5.
20. Ichikado K, Suga M, Sakamoto N, Hara S, Kakugawa T,Tsubamoto M, et al. Prediction of prognosis for acuterespiratory distress syndrome with thin section CT:validation in 44 cases. Radiology. 2006;238(1):321-9.
21. McQueen F, Solanki K. Rituximab in diffuse systemic sclerosis:should we be using it today? Rheumatology. 2015;54(5):757-67.